Class action suit against nrx pharmaceuticals dismissed

Radnor, pa. , june 22, 2022 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals"), a clinical-stage, biopharmaceutical company, is pleased to announce that on june 13, 2022, the plaintiffs in the securities class action lawsuit captioned "dal bosco v.
NRXP Ratings Summary
NRXP Quant Ranking